Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BIRC2 | Q13490 | 14/20 | 0.42 |
| ▸ | XIAP | P98170 | 11/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | BIRC3 | Q13489 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608875 | 1.00 | TSHR (0.44) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL9609030 | 0.89 | TSHR (0.48) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL3732542 | 0.89 | TSHR (0.48) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL13260038 | 0.85 | BIRC2 (0.48) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL3729220 | 0.85 | BIRC2 (0.48) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL13260178 | 0.85 | BIRC2 (0.48) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL3726069 | 0.85 | XIAP (0.45) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL9609015 | 0.85 | XIAP (0.45) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL13260180 | 0.85 | BIRC2 (0.47) | TSHRBIRC2XIAPCASP9BIRC3 | |
| SCHEMBL3726008 | 0.85 | BIRC2 (0.47) | TSHRBIRC2XIAPCASP9BIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | TSHR 3117/4885BIRC2 259/4885XIAP 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.